Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Endometriosis Market Growth in 2025?

There has been a rapid expansion in the endometriosis market size over recent years. The market will see a rise from $1.4 billion in 2024 to $1.55 billion in 2025, growing at a compound annual growth rate (CAGR) of 10.2%. Factors contributing to this growth during the historic period are attributed to delayed detection and increased cognizance, progress in laparoscopic surgery, hormonal treatments, patient advocacy, and support groups.

What Is the Forecast for the Endometriosis Market Size Through 2029?

The market size for endometriosis is predicted to witness significant expansion in the upcoming years, reaching $2.21 billion by 2029 with a 9.3% compound annual growth rate (CAGR). The anticipated growth in this specific period is the result of factors like minimal invasive procedures, advancements in pharmaceuticals, genetic and epigenetic studies, along with the worldwide extension of women’s healthcare. Key emerging trends during the forecast period encompass patient-focused care, precision medicine, virtual care, telemedicine, and fertility preservation.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13035&type=smp

What are the Key Market Players in Endometriosis Market and How They’re Evolving?

Major companies operating in the endometriosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck And Co. Inc., Abbvie Inc., Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, AstraZeneca PLC, Abbott Laboratories, Eli Lilly and Company, Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Ipsen Pharma Biotech S.A.S., Cadila Pharmaceuticals Ltd., Gedeon Richter PLC, Torrent Pharmaceuticals Ltd., Neurocrine Biosciences Inc., Ferring Pharmaceuticals, Prestige Consumer Healthcare Inc., Almirall S.A, Evotec BioSystems GmbH, Serum Institute of India Pvt. Ltd., Kissei Pharmaceutical Co. Ltd., Sanofi India Ltd., DebioPharm Group, Repros Therapeutics Inc., Meditrina Pharmaceuticals Private Limited, Zenomed Healthcare Private Limited.

What Are the Primary Growth Drivers in the Endometriosis Market?

The anticipated rise in cases of ovarian cancer is forecasted to stimulate the endometriosis market’s expansion. Originating in the ovaries – the female reproductive organs tasked with egg and hormone production – ovarian cancer is intricately connected to endometriosis. Endometriosis elevates the likelihood of developing epithelial ovarian cancer, predominantly the subtypes known as endometrioid and clear cell cancer. These subtypes are linked with heightened estrogen concentrations that further enhance the risk of the aforementioned cancer. As pointed out by the American Cancer Society in January 2023, it is anticipated that approximately 19,710 new ovarian cancer patients will emerge among American women that year. Additionally, the Ovarian Cancer Research Alliance indicated in 2022 that there were 12,810 deaths caused by ovarian cancer that year, a figure that rose to 13,270 in 2023. Consequently, this rise in ovarian cancer incidence is fueling the endometriosis market’s growth. The endometriosis market is projected to be invigorated by the surge in government funding. This term refers to the financial backing that non-government organizations receive partially or entirely from governmental bodies. Funds for endometriosis research are generally channelled through grants and contracts for individual researchers and institutions conducting clinical research. For example, in March 2022, the U.S. federal government dedicated $92 million to the National Institute of Child Health and Human Development (NICHD) and sustained its $370 million aid for the Department of Defense’s Peer-Reviewed Medical Research Programme (PRMRP) dedicated to endometriosis research. Hence, the escalation in government funding is stoking the growth of the endometriosis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13035&type=smp

What Are the Leading Segments in the Global Endometriosis Industry?

The endometriosis market covered in this report is segmented –

1) By Type: Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis, Other Types

2) By Treatment Type: Hormonal Therapy, Pain Management

3) By Drug: Oral Contraceptives, Progestins, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Gonadotropin Releasing Hormone (GnRH) Analogues, Levonorgestrel-Releasing Intrauterine Devices (LNR-IUDs), Other Drugs

4) By End-User: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Superficial Peritoneal Lesion: Endometriotic Nodules, Peritoneal Endometriosis

2) By Endometrioma: Chocolate Cysts

3) By Deeply Infiltrating Endometriosis: Bowel Endometriosis, Ureteral Endometriosis, Vaginal Endometriosis

4) By Other Types: Abdominal Endometriosis, Thoracic Endometriosis

What Are the Key Market Trends in the Endometriosis Industry?

Major players in the endometriosis market are honing their focus on the creation of innovative drugs like Myfembree, in order to offer fresh treatment alternatives for patients. The arrival of these groundbreaking endometriosis drugs meets a previously untapped need for efficient treatment options. Take, for example, the approval of Myfembree by Myovant Sciences GmbH, a Swiss-based biopharma firm, and Pfizer Inc., a U.S. pharmaceutical company, by the U.S. Food and Drug Administration (FDA) in August 2022. This approval was for the management of moderate to acute endometriosis pain in premenopausal women. Myfembree, a daily pill with a mixture of three vital components – relugolix, estradiol, and norethindrone acetate – offers proven alleviation for premenopausal women, combining two indications in a single pill. It presents a new treatment choice for women unable or reluctant to use hormone therapy.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/endometriosis-global-market-report

What Is the Regional Outlook for the Endometriosis Market?

North America was the largest region in the endometriosis market in 2024. The regions covered in endometriosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13035

This Report Delivers Insight On:

1. How big is the endometriosis market, and how is it changing globally?

2. Who are the major companies in the endometriosis market, and how are they performing?

3. What are the key opportunities and risks in the endometriosis market right now?

4. Which products or customer segments are growing the most in the endometriosis market?

5. What factors are helping or slowing down the growth of the endometriosis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model